Accès libre

A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights

Xing Li

Xing Li

College of Automation Engineering, Nanjing University of Aeronautics and AstronauticsNan Jing, China
Recherchez cet auteur sur
Sciendo|Google Scholar
Li, Xing
, 
Kaida Liu

Kaida Liu

College of Automation Engineering, Nanjing University of Aeronautics and AstronauticsNan Jing, China
Recherchez cet auteur sur
Sciendo|Google Scholar
Liu, Kaida
, 
Lidong Xing

Lidong Xing

College of Automation Engineering, Nanjing University of Aeronautics and AstronauticsNan Jing, China
Recherchez cet auteur sur
Sciendo|Google Scholar
Xing, Lidong
 et 
Boris Rubinsky

Boris Rubinsky

Department of Mechanical Engineering, University of California BerkeleyBerkeley, United States of America
Recherchez cet auteur sur
Sciendo|Google Scholar
Rubinsky, Boris
  
04 sept. 2023
A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights's Cover Image
À propos de cet article
Article précédent
Article suivant
Citez
Télécharger la couverture
Catégorie d'article: Review
Publié en ligne: 04 sept. 2023
Pages: 279 - 291
Reçu: 20 juil. 2023
Accepté: 04 août 2023
DOI: https://doi.org/10.2478/raon-2023-0044
Mots clés
© 2023 Xing Li et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

FIGURE 1.

The process of TTFields clinical trials on typical tumor types.
The process of TTFields clinical trials on typical tumor types.

FIGURE 2.

Clinical trials of TTFields treatment on glioblastoma multiforme (GBM)EF-11= controlled randomized phase III trial EF-11; EF-14 = phase III trial EF-14; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide
Clinical trials of TTFields treatment on glioblastoma multiforme (GBM)EF-11= controlled randomized phase III trial EF-11; EF-14 = phase III trial EF-14; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide

FIGURE 3.

Clinical trials of TTFields treatment on malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).EF-15 phase I/II = clinical trial NCT00749346; LUNAR = clinical trial NCT02973789; OS = overall survival; PFS = progression-free survival; STELLAR = clinical trial NCT 02397928
Clinical trials of TTFields treatment on malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).EF-15 phase I/II = clinical trial NCT00749346; LUNAR = clinical trial NCT02973789; OS = overall survival; PFS = progression-free survival; STELLAR = clinical trial NCT 02397928

FIGURE 4.

Clinical trials of TTFields treatment on platinum-resistant ovarian cancer (PROC), pancreatic adenocarcinoma (PAC) and hepatocellular carcinoma (HCC).AEs = adverse events; INNOVATE = a phase I/II clinical trial (EF-22, NCT02244502) and a phase III randomized controlled clinical trial (EF-28, NCT03940196); OS = overall survival; QoL = quality of life (QoL); PANOVA = a phase I/II clinical trial (EF-20, NCT01971281) and a larger randomized clinical phase III (EF-27, NCT03377491); PFS = progression-free survival
Clinical trials of TTFields treatment on platinum-resistant ovarian cancer (PROC), pancreatic adenocarcinoma (PAC) and hepatocellular carcinoma (HCC).AEs = adverse events; INNOVATE = a phase I/II clinical trial (EF-22, NCT02244502) and a phase III randomized controlled clinical trial (EF-28, NCT03940196); OS = overall survival; QoL = quality of life (QoL); PANOVA = a phase I/II clinical trial (EF-20, NCT01971281) and a larger randomized clinical phase III (EF-27, NCT03377491); PFS = progression-free survival

FIGURE 5.

Researches on potential mechanisms of TTFields action.
Researches on potential mechanisms of TTFields action.
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Médecine, Médecine clinique, Médecine interne, Hématologie, oncologie, Radiologie
RSS Feed de la revue